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BEAM is a widely used conditioning regimen for
relapsed/refractory lymphoma patients undergoing auto-
SCT. We conducted a multicenter study with an alter-
native regimen (fotemustine plus etoposide, cytarabine
and melphalan (FEAM)) in which BCNU was substituted
by the chloroethylnitrosourea fotemustine (FTM). Eighty-
four patients with relapsed/refractory Hodgkin’s (n¼ 20)
and non-Hodgkin’s lymphoma (n¼ 64) were conditioned
with a FEAM regimen (FTM 150mg/m2 on days –7, –6,
etoposide 200mg/m2 and cytarabine 400mg/m2 on days
–5, –4, –3, –2 and melphalan 140mg/m2 on day –1).
Patients were evaluated for toxicity and engraftment
parameters. Median times to neutrophil (4500 109/l)
and plt (420 000 109/l) engraftment were 11 and
13 days, respectively. Grade 3 mucositis occurred in
19 patients (23%), while G3 nausea/vomiting and G3
diarrhea were observed in 13 (15%) and 6 (7%) patients,
respectively. No severe hepatic, renal or pulmonary
toxicity was detected. Seven patients (7%) experienced
G4 mucositis, while no other G4 toxicities or unexpected
adverse events of any grade were recorded. Transplant-
related mortality was 2.4%. We conclude that a FEAM
regimen is feasible and safe. Although toxicity and
engraftment times compared favorably with BEAM,
longer follow-up is needed to evaluate fully its efficacy
and long-term safety.
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Introduction
BEAM is a widely adopted conditioning regimen for
autologous hemopoietic SCT (ASCT) in patients with
Hodgkin’s (HL) and non-Hodgkin’s lymphoma (NHL),
and has an acceptable toxicity and high efficacy.1 Adverse
events associated with carmustine-containing conditioning
regimens (that is, BEAM, BEAC) are partly related to
BCNU and most commonly include severe mucositis,
chemotherapy-induced nausea and vomiting, diarrhea,
hepatotoxicity and nephrotoxicity.1–4 In addition, non-
infective toxic pulmonary complications have been repor-
ted in 16–64% of patients after carmustine-containing
high-dose regimens.5 Post transplant lung toxicity in
patients receiving carmustine-based conditioning has been
related to the fact that BCNU inhibits the glutathione
reductase tissue detoxification system.6 As BCNU-related
major pulmonary toxicity represents an invalidating and
sometimes fatal complication of ASCT, accurate monitoring
of respiratory functions, prompt initiation of steroid therapy
and even carmustine dose reductions, especially in BCNU
plus CY-containing regimens, have been suggested.5,7
Fotemustine (FTM) is a third-generation chloroethyl-
nitrosourea containing a phosphoalanine carrier group
attached to the nitrosourea radical.8 The phosphoalanine
group makes the drug highly lipophilic, as shown by the
octanol/water partition coefficient, which is in the optimal
range compared with other nitrosoureas such as BCNU
and CCNU.9,10 This characteristic allows FTM to cross the
blood-brain barrier (BBB), as shown by experimental
studies in animals.11,12 In addition, as FTM does not
significantly alter glutathione reductase activity, a more
favorable pulmonary toxicity profile for this agent can be
predicted compared with BCNU.13 In fact, several clinical
trials have confirmed that FTM, unlike other nitrosoureas,
shows no significant pulmonary toxicity.14–16
With regards to antitumor activity, a phase II study by
Jacquillat et al.,17 showed that administration of a non-
myeloablative schedule of FTM (100mg/m2 on days 1, 8
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and 15 (induction), followed after 4–5 weeks by a single
100mg/m2 maintenance dose, every 21 days), induced
objective clinical responses in 7 of 13 heavily pre-treated
patients with hematologic malignancies including HL and
NHL; thrombocytopenia was the most commonly observed
toxicity. In addition, Rigal-Huguet et al.18 conducted an
intensification pilot study with autotransplantation of BM
in NHL patients in which high-dose FTM was substituted
for BCNU in modified BEAM/BEAC-like regimens (FTM,
300mg/m2; etoposide 500mg/m2; cytarabine, 400mg/m2
and melphalan 140mg/m2 or CY 6.0 g/m2).
The aim of this pharmacokinetic study was to show the
passage of FTM through the BBB and the feasibility of
increasing the dose of the drug.
Given the comparable antitumor activity of FTM
with respect to BCNU, in addition to a more favorable
safety profile, we conducted a multicenter study of a novel
FTM-based high-dose regimen (fotemustine plus etoposide,
cytarabine and melphalan (FEAM)) in which BCNU was
substituted by an equal dose (300mg/m2) of FTM without
further modifications of the BEAM platform. The results,
in a series of 84 consecutive patients with refractory and
relapsed lymphoma, show that FEAM, followed by auto-
logous hemopoietic rescue with peripheral blood progeni-
tor cells, is a feasible conditioning strategy associated




In all, 84 eligible patients with relapsed/refractory HL
(n¼ 20) or NHL (n¼ 64), were consecutively enrolled.
The study was conducted according to the Declaration of
Helsinki, and all patients signed a written informed consent
form before treatment. Eligible patients were required to
have histologically proven relapsed/refractory HL or NHL
after first-line chemotherapy. High-risk patient candidates
to upfront high-dose consolidation and ASCT were also
accrued. Other eligibility criteria included a Karnofsky
Performance Status 460, adequate cardiac, pulmonary,
hepatic and renal function, and no acute or uncontrolled
bacterial or viral infections before transplantation. Patients
with uncontrolled comorbid conditions or active toxicity
from salvage chemotherapy were considered ineligible.
Conditioning regimen
In all of the cases peripheral blood was used as the source
of CD34þ cells for transplantation. CD34þ cells were
collected by standard apheresis procedures. The FEAM
regimen consisted of FTM 150mg/m2 on days –7, –6,
etoposide 200mg/m2 and aracytin 400mg/m2 on days –5,
–4, –3, –2 and melphalan 140mg/m2 on day –1 (Table 1).
Fotemustine (Muphoran, Servier; Thissen Laboratoires,
Braine L’alleud, Belgium), was dissolved in the alcoholic
solvent, diluted in polyvinyl chloride bags containing 5%
dextrose solution, and administered i.v. over a 1-h period.
All other drugs were administered according to a standard
BEAM regimen.1 After a day of rest, autologous peripheral
blood progenitor cells were infused on day 0, followed
by s.c. G-CSF (5 mg/kg) from day 1 of ASCT until
2 consecutive days when the ANCs were X1000 109/l.
Prophylaxis for opportunistic infections and antimicrobial
therapy in cases of febrile episodes as well as standard
supportive measures including blood and plt transfusions
were administered according to the standard protocols and
policies of each participating center. Similarly, protocols
for antiemetic prophylaxis used during FEAM administra-
tion, were identical to those currently used for BEAM at
participating centers and consisted of serotonin 5-HT3-
receptor antagonists and dexamethasone.
Study definitions, safety and efficacy evaluations
The primary objectives of the study were to assess the
feasibility and safety of the FEAM regimen in terms of
acute toxicity and hemopoietic engraftment. Toxicity was
graded according to the National Cancer Institute
Common Terminology Criteria version 3.0 (http://ctep.
cancer.gov/protocoldevelopment/electronic_applications/docs/
ctcaev3.pdf). Transplant-related mortality (TRM) was
defined as any death related to a fatal complication in the
absence of the underlying disease within 100 days from
transplantation. Secondary end points included evaluation
of the efficacy of the FEAM regimen in terms of event free
survival and overall survival. Disease status at transplant-
ation and response to high-dose chemotherapy, assessed 1
month after ASCT, were evaluated with standard response
criteria for lymphoma.19 Event free survival was defined as
the time between ASCT and the occurrence of a serious
morbidity (that is, a life-threatening complication requiring
hospitalization or prolonging ongoing hospitalization
resulting in death or significant disability/incapacity),
disease relapse, disease progression or death from any
cause. Overall survival was defined as the time from ASCT
until death or the date of last follow-up when the patient
was known to be alive.
Results
Patient characteristics
From April 2007 to August 2008, a total of 84 consecutive
patients from six different institutions were enrolled.
Baseline demographics, histology, disease and patient
status before ASCT are summarized in Table 2. Twenty
patients were affected by HL (24%), and 64 by NHL (76%)
with aggressive (n¼ 57) or indolent (n¼ 7) histology. All
patients with HL received standard adriamycin, bleomycin,
vinblastine, dacarbazine as first-line therapy but in one
Table 1 Dosage and schedule of the FEAM regimen
Drug Dose Day
FTM 150mg/m2 –7, –6
Etoposide 200mg/m2 –5, –4, –3, –2
Ara-C 400mg/m2 –5, –4, –3, –2
Melphalan 140mg/m2 –1
Abbreviations: FEAM¼ fotemustine plus etoposide, cytarabine and
melphalan; FTM¼ fotemustine.
Fotemustine-based conditioning for autologous transplant
M Musso et al
1148
Bone Marrow Transplantation
case treated with bleomycin, etoposide, adriamycin, CY,
vincristine, procarbazine, prednisone whereas upfront
chemotherapy included rituximab plus CY, adriamycin,
vincristine and prednisone (n¼ 36) and rituximab plus CY,
adriamycin, vincristine and prednisone-like (Mega-CHOP,
ProMACE-CytaBOM, Hyper-CVAD, CODOX-M) regi-
mens (n¼ 21) in those with aggressive and very aggressive
NHL. Patients with indolent histology were treated upfront
with R-fludarabine-based regimens (n¼ 2) or rituximab
plus CY, adriamycin, vincristine and prednisone (n¼ 5).
After first-line chemotherapy, 24 patients were chemo-
refractory while 60 were considered chemosensitive
having attained a CR (n¼ 39) or a PR (n¼ 21) (Figure 1).
Salvage chemotherapy included ifosfamide-based regimens
(ifosfamide, carboplatin, etoposide; ifosfamide, epiribicin,
vinorelbine; ifosfamide, gemcitabine, etoposide, vinorel-
bine; and gemcitabine, ifosfamide, oxaliplatin) in 59% of
cases, sequential high-dose MTX, cytarabine and etoposide
in 12% of patients. All remaining patients (27%) were
salvaged with the high-dose dexamethasone, cytarabine,
cisplatin regimen, whereas bleomycin, etoposide, adria-
mycin, CY, vincristine, procarbazine, prednisone was used
in two patients with HL who received adriamycin,
bleomycin, vinblastine, dacarbazine as first-line therapy.
A majority of the patients (81%) had advanced disease
at relapse with BM (25%) and/or central nervous system
involvement (6%). After salvage treatment, 41 patients
achieved CR, 32 obtained a PR, while 11 patients under-
went FEAM conditioning with non-chemosensitive disease.
In all, 4 and 13 patients received mediastinal XRT
immediately before and after ASCT, respectively (Table 2).
Median days of hospitalization were 24 days (range 14–42),
five patients (6%) were admitted in intensive care unit.
Hematopoietic engraftment, transfusion support and febrile
neutropenia assessment
All patients showed timely engraftment of infused periph-
eral blood progenitor cells (Table 3), with a median time to
neutrophil recovery (4500 109/l) of 11 days (range 9–19
days). Plt recovery (420 000 109/l) was recorded after a
median of 13 days (range 6–105 days). CD34þ cells were
collected from peripheral blood and the median number of
infused cells per patient was 4.5 106/kg.
RBCs and plts transfusion support was required by
65.5 and 98.8% of patients, respectively. Neutropenic fever
occurred in 67 patients (79.8%), with a median duration of
4 days (range 1–25). The origin of fever was documented
in 29 out of 67 patients (43%) including 10 cases of
bacteremia (Escherichia coli, n¼ 4; Staphylococcus aureus,
n¼ 4; Enterobacter Cloacae, n¼ 2), 3 cases of catheter-
related infection because of coagulase-positive Staphylo-
coccus organism (n¼ 2) and Pseudomonas aeruginosa
(n¼ 1), 6 cases of enteritis (Enterococcus faecium, n¼ 1,
E. Coli, n¼ 5), 6 cases of upper respiratory tract infections
(Staphylococcus aureus, n¼ 3; Streptococcus pneumoniae,
n¼ 3) and 4 cases of urogenital tract infections (Klebsiella,
n¼ 2; E. Coli, n¼ 2).
The remaining 38 patients (56.7%) had negative results
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Figure 1 Study flow-chart throughout the treatment and follow-up
periods. cCR, continuous CR; cPR, continuous PR; cRD, continuous
RD; ED, early death; RD, refractory disease; PD, progression of disease.
Table 2 Patient characteristics
n (%)
Total no. of patients 84
Age, years













Bone marrow 21 (25)
CNS 5 (6)





Before ASCT 4 (4.8)
After ASCT 13 (15.5)




Abbreviations: ASCT¼ autologous stem cell transplantation; CNS¼
central nervous system; CT¼ chemotherapy; HL¼Hodgkin’s lymphoma;
NHL¼ non-Hodgkin’s lymphoma; RD¼ refractory disease.
aIncluding diffuse large B-cell lymphoma, n¼ 37; lymphoblastic lympho-
ma, n¼ 7; mantle cell lymphoma, n¼ 6; and peripheral T-cell lymphoma,
n¼ 7.
bIncluding lymphoplasmacytic/small lymphocytic lymphoma, n¼ 5 and
follicular lymphoma, n¼ 2.
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Treatment-related morbidity and mortality
Treatment-related toxicity, according to National Cancer
Institute Common Terminology Criteria, is summarized in
Table 4. Overall, FEAM conditioning was well tolerated.
Mucositis reached G3/G4 severity in only 30% of cases
(median duration 7 days, range 4–14), while G2/G3
chemotherapy-induced nausea and vomiting was documen-
ted in 47% of patients, without any G4 episodes. Similarly,
17 and 7% of patients experienced G2 and G3 diarrhea,
while no G4 events were observed. Liver and renal toxicity
was generally mild and transient, with G2 events being
recorded in only 2 and 1% of patients, respectively. There
were no episodes of veno-occlusive liver disease. Adminis-
tration of FEAM was not associated with pulmonary
adverse events, except for a single case of G2 toxicity in a
patient with a concomitant bacterial respiratory infection,
one case of G1 laryngitis, and a single episode of G1
dyspnea. TRM at 100 days occurred in two patients
(2.4%); one died of bacterial meningitis at day þ 25 after
transplantation, and the other of bacterial infection at day
þ 51 after having achieved full hematologic recovery.
Patient outcome and survival
As shown in Figure 1 and Table 5, 73 out of 84 patients
(86.9%) had chemosensitive disease (41 CR, 32 PR) before
ASCT, while in 11 patients (13.1%) the progressing lym-
phoma was chemorefractory to salvage therapy. Regarding
post-FEAM conditioning and ASCT, 70 out of 84 (83.3%)
patients attained CR, 7 achieved PR (8.3%), 6 patients
(7.2%) showed no response (three because of refractory
disease and three because of early progression), and 1 was
not assessable as the patient died of TRM. Interestingly,
FEAM conditioning was active in partially responsive and
chemoresistant diseases as shown by a 78% conversion rate
of PR into CR and by the attainment of an objective
response (six CR and two PR) in about 70% of patients
with chemorefractory lymphoma at transplantation. After
a median follow-up of 13 months (range 1–23), 74 patients
(88.1%) were alive (Table 5). In particular, of the 70
patients attaining CR, 58 (82.9%) were alive and disease
free, 9 were alive with lymphoma progression (occurred
at days þ 164, þ 179, þ 226, þ 304, þ 370, þ 375, þ 379,
þ 413 and þ 615, post-ASCT), 1 (70-year old) died for
TRM at day þ 51, because of infection, 1 (68-year old)
died of disease progression at day þ 186 and 1 (71-year old)
died for cardiac comorbidity at day þ 175. Among the 84
patients, 10 deaths occurred during a median follow-up of
Table 4 Toxicity associated with the FEAM regimen
Type of toxicity Grade 0 (%) Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%)
Mucositis 13 (15) 10 (12) 36 (43) 19 (23) 6 (7)
CINV 18 (22) 26 (31) 27 (32) 13 (15) 0
Diarrhoea 50 (59) 14 (17) 14 (17) 6 (7) 0
Hepatotoxicity 82 (98) 0 2 (2) 0 0
Nephrotoxicity 83 (99) 0 1 (1)a 0 0
Pulmonary toxicity 81 (96) 2 (2)b 1 (1)c 0 0
Abbreviation: CINV¼ chemotherapy-induced nausea and vomiting.
aTransient renal toxicity in a 70-year-old patient.
bOne episode of laryngitis and one of dyspnea.
cSlight thickening of the lungs due to concomitant Klebsiella and Pseudomonas aeruginosa infection.
Table 3 Hematopoietic engraftment, transfusion support therapy,
infection and febrile neutropenia
Parameter Outcome
Hematopoietic engraftment Median (range)
Number of CD34+a cells infused ( 106/kg) 4.5 (1–21.8)
Median days (range)
Neutrophils (4500 109/l) 11 (9–19)
Neutrophils (41000 109/l) 12 (9–20)
Plts (420 000 109/l) 13 (6–105)
Plts (450 000 109/l) 16.5 (10–105)
Transfusion support therapy n (%)
RBC unitsb 55 (65.5)
Median (range) 2 (1–8)
Plt unitsc 83 (98.8)
Median (range) 2 (1–15)
Febrile neutropeniad n (%)
No 17 (20.2)
Yes 67 (79.8)





Abbreviations: FUO¼ fever of unknown origin; MDF¼microbiologically
documented fever.
aCD34+: source of collection was peripheral blood.
bThe red blood transfusion threshold was a hemoglobin value o8g per
100ml.
cThe platelet transfusion threshold was a platelet count o20 000 109/l.
dFever 438 1C and a number of neutrophils o500 109/l.
eNumber of patients with Gram±infection among patients with FUO.
Table 5 Patient status throughout treatment and follow-up





Follow-up median 13 months
(range 1–23 months)
CR 41 (48.8) 70 (83.3) 58 (69.0)
PR 32 (38.1) 7 (8.3) 4 (4.8)
RD 11 (13.1) 3 (3.6) 0
PD 3 (3.6) 12 (14.3)
Death 1 (1.2) 10 (11.9)
Abbreviations: ASCT¼ autologous stem cell transplantation; RD, refrac-
tory disease; PD¼ progressive disease.
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13 months. Four patients died of disease progression at
days þ 207, þ 45, þ 78, þ 108 at 33, 41, 63, 65 years old,
respectively, one patient (52-year old) died of meningitis at
day þ 25, one (39-year old) for hemorrhage at day þ 112
and one (64-year old) because of comorbidity at day þ 210.
Discussion
High-dose chemotherapy followed by ASCT is an estab-
lished treatment modality for recurrent lymphoma that is
associated with long-term survival in 30 to 50% of patients
with HL and NHL that fail upfront multiagent chemo-
therapy.20–23 Clinical outcome and survival of lymphoma
patients after ASCT depend, among other factors, on the
disease chemosensitivity at transplantation, ability of
conditioning regimens to eradicate residual tumor cell
clones after salvage chemotherapy, and transplant-related
morbidity and mortality.4,20,22–24 Despite efforts to identify
high-dose regimens with increasing antitumor activity and
acceptable toxicity to normal tissues, there is not yet clear
evidence of a superior conditioning platform that should be
applied in the setting of recurring lymphoma patients, at
least in terms of tumor-eradicating capacity. Consequently,
most recent research has focused on the incorporation of
monoclonal antibodies, radioimmunoconjugates and other
immunologic manipulations during the early pre- and post
transplantation phases.25–27 However, because some major
causes of both early- and long-term mortality after ASCT
remain related to the toxicity of the high-dose regimen
adopted, efforts to ameliorate tolerability and reduce the
extrahematologic toxicity of conditioning regimens may be
a further means to improve patient outcomes.
BEAM is the most widely used conditioning regimen for
ASCT in patients with HL and NHL, and has acceptable
toxicity and high antitumor efficacy.1–4,28 The early
nonhematologic toxicities of BCNU, the nitrosourea
component of BEAM, have been fully characterized and
mainly represented by mucositis, nausea and vomiting,
diarrhea, hepatotoxicity and nephrotoxicity.1–4,22,28,29 In
addition, late-onset toxic pulmonary reactions, mainly
interstitial non-infectious pneumonitis, have been reported
in 16–64% of patients receiving BCNU-based conditioning
regimens, with a fatal outcome in about 9% of cases.5,7,29–31
BCNU-related pulmonary toxicity appears to be dose
related and is probably linked to BCNU-specific inhibi-
tion of the glutathione reductase cellular detoxification
system.5,6 Although dose reductions, early steroid therapy
and intensive respiratory monitoring have been adopted to
manage carmustine-related lung injury in patients receiving
carmustine-based conditioning regimens,5 an alternative
approach is to replace BCNU with an equally active agent
with a more favorable toxicity profile.
In this study, we report the results of a multicenter study
in which 84 consecutive patients with recurring lymphoma
were conditioned with a modified BEAM-like regimen
(FEAM) in which carmustine was substituted by the third-
generation chloroethylnitrosourea FTM.8,32 In this regard,
FTM shows a distinct pharmacologic and safety profile
with respect to both first- (lomustine) and second- (BCNU)
generation nitrosoureas, which is characterized by a
reduced incidence of hepatic and renal complications and
by the absence of pulmonary toxicity.33 In addition, FTM
shows antitumor activity that is comparable to BCNU, and
preclinical and clinical studies have shown that it has
significant cytotoxicity toward malignant lymphoid
cells.17,18,34–39
All patients showed timely hemopoietic engraftment
after FTM-based conditioning, with neutrophil and plt
recovery to post transplant intervals that are highly
comparable to those reported for most carmustine-based
regimens.1–4,22,28,29 Similarly, the intensity of transfusion
support and the rate, type, and severity of neutropenic
infectious episodes during the aplastic phase did not
substantially differ from those reported for BEAM and
BEAM-like regimes,1–4,22,29 thus confirming the overall
safety of FEAM conditioning. This is further confirmed by
a TRM of 2.4%, which compares favorably with that
reported for similar carmustine-based regimens (0 to 11%)
and other types of high-dose conditioning (0 to 25%), with
variations being mostly related to patient age and/or
comorbidity status.1–4,22,28–30,40–42
Regarding the acute toxicity of FEAM, we observed a
relatively high incidence of mucositis, which was, however,
equal or higher than G3 severity in only 30% of episodes.
Although the design of this study did not foresee
comparison with standard BEAM, it is noteworthy that a
recent investigation reported that 83% of patients receiving
BEAM experienced oral mucositis, which was graded
G1/G2 in 42% of cases and G3/G4 in the remaining 41%
of patients.42 In our series, we detected a similar overall
incidence of mucositis (85%), but the substitution of
BCNU with FTM appeared to be associated with a shift
toward less severe mucositis (G2, 43%; G3/G4, 30%), with
the apparent reduction of G4 episodes to 7% compared
with 18% reported for BEAM.41,42 A favorable trend for
FEAM can be also envisaged for chemotherapy-induced
nausea and vomiting, and diarrhea, because no G4 toxic
episodes were recorded in our cohort, leading to overall
G3/G4 rates of 15 and 7%, respectively. Other large series
of patients conditioned with BEAM have reported that the
incidence of G3/G4 chemotherapy-induced nausea and
vomiting, and diarrhea ranges from 15–20 to 22–25%,
respectively.1–4,28,29 FEAM was also associated a very low
rate of renal (1%) and hepatic (2%) G2 adverse events.
This confirms data from preclinical studies in which
Laquerriere et al.33 compared the hepatic tolerability of
FTM to BCNU and CCNU. In that in vitro study in rat
hepatocytes, it was shown that FTM was not directly
hepatotoxic, and produced only modest and reversible
changes in the biochemical functions of liver cells, in
contrast to other nitrosoureas that caused substantial
disturbances in cell cycle progression.33 Accordingly, no
veno-occlusive liver disease episodes occurred in our cohort
of patients.
Considering pulmonary adverse events, we observed no
G3/G4 toxicity, and only a single G2 episode of slight
thickening of the interlobular septa in a symptomatic
patient with microbiologically documented Klebsiella and
Pseudomonas aeruginosa infection. The episode resolved
on targeted antibiotic therapy, thus minimizing its
qualification as a typical drug-induced non-infectious
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pulmonary complication (NIPC).5 In addition, there was
one transient episode of G1 exertion dyspnea and a G1
larynx edema. Both events quickly resolved without steroid
therapy. The median time to development of non-infectious
pulmonary complications in patients conditioned with
carmustine-based regimes was 90 days post-ASCT (range
52–289), with later episodes occurring within the year.5
Although the delayed occurrence of non-infectious
pulmonary complications in some patients cannot yet be
excluded, the present data suggest that the FEAM regime is
not associated with a significant risk of moderate-to-severe
pulmonary complications.
The relatively short follow-up of our study does not
allow any conclusions in terms of survival or the long-term
efficacy of FEAM conditioning. However, it is noteworthy
that the regimen achieved CRs in chemoresistant cases,
converted a pre-transplantation PR status into CR in
several patients, and that, at a median follow-up of 13
months (range 1–23 months), 56 patients (80%) achieving
CR after transplantation were alive and disease free.
Interestingly, none of the four patients with documented
central nervous system involvement before ASCT showed,
at the longest follow-up of 17 months, any disease
progression at the level of the central nervous system,
which is consistent with the active passage of FTM through
the blood-brain barrier. Three of these patients are in
continuous CR, one died of causes unrelated to lymphoma.
Considering the limits of the study design, we have
shown that substitution of the less toxic FTM for BCNU
within the BEAM conditioning regimen is both feasible and
safe. The FEAM regimen was associated with hemopoietic
recovery times comparable to carmustine-containing re-
gimes, and was devoid of unexpected adverse events. It also
showed a very favorable acute toxicity profile with regards
to mucositis and hepatic, renal, and pulmonary complica-
tions. Although a longer follow-up is needed to evaluate the
clinical efficacy and long-term safety, these promising
results may also prompt a randomized comparison of
FEAM vs standard carmustine-based regimens.
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